Michael D. P
Mr. Parker brings a wealth of experience to Sigmoid, with 34 years at The Dow Chemical Company, where he was President and CEO from 2000 to 2002, and where he had a number of previous leadership roles in research, manufacturing and commercial in the USA, UK, Switzerland and Hong Kong. He served as CEO at British Nuclear Fuels PLC (BNFL) from 2005 to 2009
SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.